| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8444123 | European Journal of Cancer | 2013 | 5 Pages |
Abstract
Our data suggest that discontinuation of imatinib is safe in patients with durable MR4.5.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Noortje Thielen, Bronno van der Holt, Jan J. Cornelissen, Gregor E.G. Verhoef, Titia Gussinklo, Bart J. Biemond, Simon M.G. Daenen, Wendy Deenik, Rien van Marwijk Kooy, Eefke Petersen, Willem M. Smit, Peter J.M. Valk, Gert J. Ossenkoppele,